title: Adjunctive therapy with bromocriptine in Parkinson's disease.
abstract: Patients with moderately severe Parkinson's disease complicated by the adverse effects of chronic levodopa use benefited from the addition of bromocriptine (Parlodel; Sandoz) in doses up to 26 mg daily, which allowed an approximate 30% reduction of levodopa dose. This resulted in a significant decrease in the amount of levodopa side-effects while maintaining or improving the original parkinsonian clinical stage. Increased effectiveness in these patients was not associated with increased dosage beyond 25-30 mg daily. When the doses of bromocriptine were increased slowly, the adverse reactions were minor and usually transient.
authors: Neurology Unit, Johannesburg Hospital.
authors: J A
authors: JA
authors: Temlett
authors: A
authors: A
authors: Ming
authors: M
authors: M
authors: Saling
authors: V U
authors: VU
authors: Fritz
authors: A
authors: A
authors: Blumenfeld
authors: T R
authors: TR
authors: Bilchik
authors: A L
authors: AL
authors: Becker
authors: P B
authors: PB
authors: Fourie
authors: H E
authors: HE
authors: Reef
mesh_terms: D000328:Adult; D000368:Aged; D001971:Bromocriptine / Q000008:administration & dosage* / Q000627:therapeutic use; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D001971:Bromocriptine; D007980:Levodopa